Description
Legend Biotech: Can The Partnership With Multiply Labs Be A Game Changer?
Legend Biotech, a biopharmaceutical company focused on cell therapies for cancer and other serious diseases, delivered robust financial performance in the third quarter of 2024. The company reported accelerating adoption and sales of its flagship product, CARVYKTI, a CAR-T (chimeric antigen receptor T) cell therapy targeting multiple myeloma. For the quarter, CARVYKTI generated approximately $286 million in net sales, reflecting an 87.6% increase year-over-year and 53.2% quarter-over-quarter. Outside the U.S. (OUS), sales more than doubled on an annual basis, aided by capacity expansion efforts and broader initial launches in international markets.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures
Want unlimited access to our reports? Purchase our $99 annual subscription!
